ALK-1/Activin RL1, His, Human

ALK-1/Activin RL1, His, Human

Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Z05005
¥55,963.00

Ask us a question
Product Introduction
Species Human
Protein Construction
ALK-1/Activin RL1 (Asp22-Gln118)
Accession # P37023		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Human GDF­2, No Tag at 2μg/ml (100μl/well) on the plate can bind ALK-1/Activin RL1, His, Human. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 11.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Synonyms ACVRLK1; ORW2; ALK1; ALK-1; EC 2.7.11; HHT; HHT2; SKR3; TSR-I; ACVRL1; Activin RLI

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.